LitAlert ~~ GeneLit.com

    • Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    • Lee EK, Matulonis UA.
    • Expert Opin Emerg Drugs. 2020 Jun 22:1-23. doi: 10.1080/14728214.2020.1773791. Epub ahead of print.
    • Review
    • Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
    • Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS.
    • J Clin Oncol. 2020 Jun 22:JCO1902404. doi: 10.1200/JCO.19.02404. Epub ahead of print.
    • The forefront of ovarian cancer therapy: update on PARP inhibitors.
    • Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S.
    • Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. doi: 10.1016/j.annonc.2020.06.004. Epub ahead of print.
    • Review
    • The DIEP Flap as Well-established Method of Choice for Autologous Breast Reconstruction with a Low Complication Rate - Retrospective Single-centre 10-Year Experience.
    • Munder B, Andree C, Witzel C, Fertsch S, Stambera P, Schulz T, Fleischer O, Hagouan M, Grüter L, Aufmesser B, Staemmler K, Kornetka J, Aldeeri M, Seidenstücker K, Abu-Ghazaleh A, Wolter A.
    • Geburtshilfe Frauenheilkd. 2020 Jun;80(6):628-638. doi: 10.1055/a-1116-2102. Epub 2020 Apr 16.